Trump Administration’s Appointment of Vaccine Skeptic to FDA Role Sparks Concern
The Trump administration’s decision to appoint Dr. Tracy Beth Høeg as the acting director of the FDA’s Center for Drug Evaluation and Research has raised eyebrows among senior FDA officials. According to sources, Høeg’s appointment has sparked widespread concern that the agency’s reputation as a reliable steward of the nation’s drug supply will be compromised. The FDA’s Center for Drug Evaluation and Research is responsible for evaluating new drugs and ensuring adequate supplies of existing ones.
Høeg’s appointment came after the abrupt resignation of Richard Pazdur, a veteran FDA scientist who took over the office just three weeks ago. Pazdur’s resignation was reportedly due to clashes with FDA Commissioner Marty Makary. Sources close to the matter claim that Pazdur had agreed to take on the role on the condition that Makary would not intervene with the office’s work. However, Makary began interviewing candidates to fill roles that Pazdur oversaw, leading to Pazdur’s resignation.
Controversy Surrounding Høeg’s Appointment
Høeg has been a controversial figure, particularly with regards to her views on vaccine safety. This fall, she advocated for making it more difficult for young men to receive the COVID vaccine due to the potential risks associated with a rare side effect called myocarditis. Høeg has also been advising Commissioner Makary on the agency’s vaccine policy and helped write a memo claiming that FDA leaders found at least 10 children had died “after and because of” receiving the COVID-19 vaccine. However, the memo offered no data to back up this claim.
Høeg’s views on vaccine safety have been met with criticism from former FDA leaders, who have denounced the proposed changes to the agency’s handling of COVID-19 and other vaccines. In a statement, a dozen former FDA leaders wrote that the proposed changes “undermine a regulatory model designed to ensure vaccine safety, effectiveness, and availability” and “represent a major shift in the FDA’s understanding of its job.”
Høeg’s Qualifications and Experience
Questions have been raised about Høeg’s qualifications and experience for the role. As a sports medicine physician and epidemiologist, Høeg has never supervised a drug review or conducted a clinical trial. Sources within the agency have expressed concern that Høeg’s lack of experience will harm the agency’s reputation and potentially lead to companies developing new products overseas, where the regulatory environment is more stable.
Despite these concerns, Commissioner Makary has expressed support for Høeg’s appointment, stating that she is “the right scientist to fully modernize” the drug regulator’s office. Makary added that Høeg has “advanced scientific rigor through her commitment to providing the public with the highest quality of evidence.”
Impact on the FDA and Public Health
The appointment of Høeg has sparked fears that the FDA will become increasingly politicized, with potential consequences for public health. The agency’s role in ensuring the safety and efficacy of drugs and vaccines is critical to protecting the public’s health. If the FDA’s reputation is compromised, it could lead to a decline in trust in the agency and the healthcare system as a whole.
As Høeg takes on her new role, she will oversee an office responsible for ensuring all over-the-counter and prescription drugs in America are safe and effective. The office is also tasked with approving new drugs and providing guidance to healthcare professionals and consumers. It remains to be seen how Høeg’s appointment will impact the FDA’s work and the public’s trust in the agency.
For more information on this story, visit Here
Image Source: www.cbsnews.com
